Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
| ▸ | WHR1 | P49842 | 1/20 | 0.44 |
| ▸ | GAK | O14976 | 3/20 | 0.42 |
| ▸ | EGFR | P00533 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | FBP1 | P09467 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16212567 | 0.87 | EGFR (0.46) | ADORA2AADORA1GAKEGFRMAPT | |
| SCHEMBL1979453 | 0.82 | EGFR (0.52) | ADORA2AGAKEGFRMAPTALDH1A1 | |
| SCHEMBL29493193 | 0.82 | EGFR (0.52) | ADORA2AGAKEGFRMAPTALDH1A1 | |
| SCHEMBL15877057 | 0.82 | DHPS (0.54) | ADORA2AADORA1WHR1EGFRMAPT | |
| SCHEMBL17940130 | 0.81 | CYP1A2 (0.47) | ADORA2AADORA1WHR1GAKEGFR | |
| Hydrochloric Acid SCHEMBL30963337 | 0.81 | EGFR (0.52) | ADORA2AGAKEGFRMAPTALDH1A1 | |
| Hydrochloric Acid SCHEMBL2839910 | 0.80 | EGFR (0.38) | ADORA2AADORA1WHR1GAKEGFR | |
| SCHEMBL2253014 | 0.78 | ABCG2 (0.49) | ADORA2AADORA1MAPTALDH1A1KMT2A | |
| SCHEMBL4077942 | 0.78 | ABCG2 (0.46) | ADORA2AADORA1MAPTALDH1A1KMT2A | |
| SCHEMBL20280955 | 0.77 | WHR1 (0.71) | WHR1MAPTALDH1A1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107556295-B | Quinazoline derivatives and process for their preparation | 正大天晴药业集团股份有限公司 | 2020-09-04 | — | — | CN | disclosed |
| EP-3050880-B1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF CANCER | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2019-06-19 | — | — | EP | disclosed |
| CN-109694355-A | The synthetic method of N- (3- alkynyl phenyl) -4,6- diamino quinazolines compounds and related intermediate | 和记黄埔医药（上海）有限公司 | 2019-04-30 | — | — | CN | disclosed |
| CN-109694370-A | The synthetic method of N- (3- alkynyl phenyl) -4,6- diamino quinazolines compounds and related intermediate | 和记黄埔医药（上海）有限公司 | 2019-04-30 | — | — | CN | disclosed |
| CN-109694356-A | The synthetic method of N- (3- alkynyl phenyl) -4,6- diamino quinazolines compounds and related intermediate | 和记黄埔医药（上海）有限公司 | 2019-04-30 | — | — | CN | disclosed |
| US-9725439-B2 | Quinazoline derivative and preparation method therefor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2017-08-08 | — | — | US | disclosed |
| US-9556191-B2 | Aminoquinazoline derivatives and their salts and methods of use thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-01-31 | — | — | US | disclosed |
| EP-3050880-A1 | QUINAZOLINE DERIVATIVE AND PREPARATION METHOD THEREFOR | Chia Tai Tianqing Pharmaceutical Group Co.,Ltd (CN) | 2016-08-03 | — | — | EP | disclosed |
| US-20160214964-A1 | QUINAZOLINE DERIVATIVE AND PREPARATION METHOD THEREFOR | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2016-07-28 | — | — | US | disclosed |
| US-9371292-B2 | Quinazoline derivative, preparation method therefor, intermediate, composition and application thereof | SHANGHAI PHARMACEUTICALS HOLDINGS CO., LTD. (CN) | 2016-06-21 | — | — | US | disclosed |
| EP-2061773-A2 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | Curis, Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20090111772-A1 | FORMULATION OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2009-04-30 | — | — | US | disclosed |
| WO-2009035718-A1 | TARTRATE SALTS OR COMPLEXES OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| US-20090076022-A1 | epidermal growth factor receptor tyrosine kinase (EGFR-TK) and histone deacetylase inhibitors such as 2-(4-(3-Chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyacetamide, used as anticarcinogenic agents | CURIS, INC. | 2009-03-19 | — | — | US | disclosed |
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | CURIS, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080194578-A1 | inhibitors of epidermal growth factor receptor tyrosine kinase and histone deacetylase; 2-(4-(3-Chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyacetamide; anticarcinogenic agent | CURIS, INC. | 2008-08-14 | — | — | US | disclosed |
| WO-2008033747-A9 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | CURIS INC (MA) | 2008-07-24 | — | — | WO | disclosed |
| US-20080139590-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2008-06-12 | — | — | US | disclosed |
| WO-2008033749-A2 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008033747-A2 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | CURIS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076022-A1 | epidermal growth factor receptor tyrosine kinase (EGFR-TK) and histone deacetylase inhibitors such as 2-(4-(3-Chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyacetamide, used as anticarcinogenic agents | EGFR, HDAC1, HDAC8 | ADORA2A 4417/4885ADORA1 4671/4885WHR1 2803/4885 |
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | HDAC1, HDAC6, HDAC5 | ADORA2A 4408/4885ADORA1 4633/4885WHR1 1555/4885 |
| US-20080194578-A1 | inhibitors of epidermal growth factor receptor tyrosine kinase and histone deacetylase; 2-(4-(3-Chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyacetamide; anticarcinogenic agent | HDAC1, HDAC8, EGFR | ADORA2A 4241/4885ADORA1 4733/4885WHR1 2391/4885 |
| US-20090111772-A1 | FORMULATION OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | HDAC6, HDAC5, HDAC1 | ADORA2A 4056/4885ADORA1 4476/4885WHR1 3533/4885 |
| US-20080139590-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | EGFR, HDAC1, HDAC6 | ADORA2A 4577/4885ADORA1 4780/4885WHR1 2457/4885 |
| US-20160214964-A1 | QUINAZOLINE DERIVATIVE AND PREPARATION METHOD THEREFOR | WEE1, WEE2, EGFR | ADORA2A 1698/4885ADORA1 631/4885WHR1 1615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.